86 related articles for article (PubMed ID: 24380864)
1. Facile "stop codon" method reveals elevated neuronal toxicity by discrete S87p-α-synuclein oligomers.
Ha Y; Yang A; Lee S; Kim K; Liew H; Suh YH; Park HS; Churchill DG
Biochem Biophys Res Commun; 2014 Jan; 443(3):1085-91. PubMed ID: 24380864
[TBL] [Abstract][Full Text] [Related]
2. Dopamine and Cu+/2+ can induce oligomerization of α-synuclein in the absence of oxygen: Two types of oligomerization mechanisms for α-synuclein and related cell toxicity studies.
Ha Y; Yang A; Lee S; Kim K; Liew H; Lee SH; Lee JE; Lee HI; Suh YH; Park HS; Churchill DG
J Neurosci Res; 2014 Mar; 92(3):359-68. PubMed ID: 24288134
[TBL] [Abstract][Full Text] [Related]
3. Dopamine and the dopamine oxidation product 5,6-dihydroxylindole promote distinct on-pathway and off-pathway aggregation of alpha-synuclein in a pH-dependent manner.
Pham CL; Leong SL; Ali FE; Kenche VB; Hill AF; Gras SL; Barnham KJ; Cappai R
J Mol Biol; 2009 Apr; 387(3):771-85. PubMed ID: 19361420
[TBL] [Abstract][Full Text] [Related]
4. Interplay of salicylaldehyde, lysine, and M2+ ions on α-synuclein aggregation: cancellation of aggregation effects and determination of salicylaldehyde neurotoxicity.
Ha Y; Liew H; Park HY; Kim K; Suh YH; Churchill DG
Neurosci Res; 2011 Oct; 71(2):168-77. PubMed ID: 21784112
[TBL] [Abstract][Full Text] [Related]
5. Modulation of human α-synuclein aggregation by a combined effect of calcium and dopamine.
Jain MK; Bhat R
Neurobiol Dis; 2014 Mar; 63():115-28. PubMed ID: 24269918
[TBL] [Abstract][Full Text] [Related]
6. The N-terminal residues 43 to 60 form the interface for dopamine mediated α-synuclein dimerisation.
Leong SL; Hinds MG; Connor AR; Smith DP; Illes-Toth E; Pham CL; Barnham KJ; Cappai R
PLoS One; 2015; 10(2):e0116497. PubMed ID: 25679387
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of alpha-synuclein fibrillization by dopamine analogs via reaction with the amino groups of alpha-synuclein. Implication for dopaminergic neurodegeneration.
Li HT; Lin DH; Luo XY; Zhang F; Ji LN; Du HN; Song GQ; Hu J; Zhou JW; Hu HY
FEBS J; 2005 Jul; 272(14):3661-72. PubMed ID: 16008565
[TBL] [Abstract][Full Text] [Related]
8. Cleavage of normal and pathological forms of alpha-synuclein by neurosin in vitro.
Kasai T; Tokuda T; Yamaguchi N; Watanabe Y; Kametani F; Nakagawa M; Mizuno T
Neurosci Lett; 2008 May; 436(1):52-6. PubMed ID: 18358605
[TBL] [Abstract][Full Text] [Related]
9. The interplay between lipids and dopamine on α-synuclein oligomerization and membrane binding.
Pham CL; Cappai R
Biosci Rep; 2013 Oct; 33(5):. PubMed ID: 24066973
[TBL] [Abstract][Full Text] [Related]
10. Redox activity of α-synuclein-Cu is silenced by Zn₇-metallothionein-3.
Meloni G; Vašák M
Free Radic Biol Med; 2011 Jun; 50(11):1471-9. PubMed ID: 21320589
[TBL] [Abstract][Full Text] [Related]
11. Baicalein inhibits formation of α-synuclein oligomers within living cells and prevents Aβ peptide fibrillation and oligomerisation.
Lu JH; Ardah MT; Durairajan SS; Liu LF; Xie LX; Fong WF; Hasan MY; Huang JD; El-Agnaf OM; Li M
Chembiochem; 2011 Mar; 12(4):615-24. PubMed ID: 21271629
[TBL] [Abstract][Full Text] [Related]
12. Guanidine hydrochloride denaturation of dopamine-induced α-synuclein oligomers: a small-angle X-ray scattering study.
Pham CL; Kirby N; Wood K; Ryan T; Roberts B; Sokolova A; Barnham KJ; Masters CL; Knott RB; Cappai R; Curtain CC; Rekas A
Proteins; 2014 Jan; 82(1):10-21. PubMed ID: 23733394
[TBL] [Abstract][Full Text] [Related]
13. Dopamine facilitates alpha-synuclein oligomerization in human neuroblastoma SH-SY5Y cells.
Yamakawa K; Izumi Y; Takeuchi H; Yamamoto N; Kume T; Akaike A; Takahashi R; Shimohama S; Sawada H
Biochem Biophys Res Commun; 2010 Jan; 391(1):129-34. PubMed ID: 19900407
[TBL] [Abstract][Full Text] [Related]
14. Disruption of dopamine homeostasis underlies selective neurodegeneration mediated by alpha-synuclein.
Park SS; Schulz EM; Lee D
Eur J Neurosci; 2007 Dec; 26(11):3104-12. PubMed ID: 18005066
[TBL] [Abstract][Full Text] [Related]
15. Structural and functional properties of prefibrillar α-synuclein oligomers.
Pieri L; Madiona K; Melki R
Sci Rep; 2016 Apr; 6():24526. PubMed ID: 27075649
[TBL] [Abstract][Full Text] [Related]
16. Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation.
Bellucci A; Collo G; Sarnico I; Battistin L; Missale C; Spano P
J Neurochem; 2008 Jul; 106(2):560-77. PubMed ID: 18410503
[TBL] [Abstract][Full Text] [Related]
17. Formation of dopamine-mediated alpha-synuclein-soluble oligomers requires methionine oxidation.
Leong SL; Pham CL; Galatis D; Fodero-Tavoletti MT; Perez K; Hill AF; Masters CL; Ali FE; Barnham KJ; Cappai R
Free Radic Biol Med; 2009 May; 46(10):1328-37. PubMed ID: 19248830
[TBL] [Abstract][Full Text] [Related]
18. Review on the interactions between dopamine metabolites and α-Synuclein in causing Parkinson's disease.
Sivakumar P; Nagashanmugam KB; Priyatharshni S; Lavanya R; Prabhu N; Ponnusamy S
Neurochem Int; 2023 Jan; 162():105461. PubMed ID: 36460239
[TBL] [Abstract][Full Text] [Related]
19. The structure of dopamine induced alpha-synuclein oligomers.
Rekas A; Knott RB; Sokolova A; Barnham KJ; Perez KA; Masters CL; Drew SC; Cappai R; Curtain CC; Pham CL
Eur Biophys J; 2010 Sep; 39(10):1407-19. PubMed ID: 20309679
[TBL] [Abstract][Full Text] [Related]
20. Serine 129 phosphorylation of membrane-associated α-synuclein modulates dopamine transporter function in a G protein-coupled receptor kinase-dependent manner.
Hara S; Arawaka S; Sato H; Machiya Y; Cui C; Sasaki A; Koyama S; Kato T
Mol Biol Cell; 2013 Jun; 24(11):1649-60, S1-3. PubMed ID: 23576548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
